CELC Stock Price, Celcuity Inc Quote, Chart

Market Summary

USD16.75-0.91

Delayed

-5.15%

CELC Stock Price

View Fullscreen

CELC RSI Chart

CELC Valuation

Market Cap

523.1M

Price/Earnings (Trailing)

-7.12

EV/EBITDA

-7.25

Price/Free Cashflow

-8.99

MarketCap/EBT

-7.12

CELC Price/Sales (Trailing)

CELC Profitability

Return on Equity

-54.92%

Return on Assets

-39.03%

Free Cashflow Yield

-11.12%

CELC Fundamentals

CELC Earnings

Earnings (TTM)

-73.5M

Earnings Growth (Yr)

-81.03%

Earnings Growth (Qtr)

-14.66%

Breaking Down CELC Revenue

Last 7 days

-0.5%

Last 30 days

-1.5%

Last 90 days

9.9%

Trailing 12 Months

68.9%

How does CELC drawdown profile look like?

CELC Financial Health

Current Ratio

11.23

CELC Investor Care

Shares Dilution (1Y)

42.22%

Diluted EPS (TTM)

-2.78

Tracking the Latest Insider Buys and Sells of Celcuity Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 26, 2024	sullivan brian f.	gifted	-	-	45,025	chief executive officer
Apr 26, 2024	sullivan brian f.	gifted	-	-	-45,025	chief executive officer
Apr 24, 2024	buller richard e	sold	-5,971	17.06	-350	-
Mar 18, 2024	sullivan brian f.	gifted	-	-	765,897	chief executive officer
Mar 18, 2024	sullivan brian f.	gifted	-	-	-765,897	chief executive officer
Feb 21, 2024	buller richard e	sold	-4,952	14.15	-350	-
Jan 30, 2024	sullivan brian f.	gifted	-	-	-85,000	chief executive officer
Jan 30, 2024	sullivan brian f.	gifted	-	-	85,000	chief executive officer
Dec 27, 2023	sullivan brian f.	gifted	-	-	-1,733,350	chief executive officer
Dec 27, 2023	sullivan brian f.	gifted	-	-	863,347	chief executive officer

Which funds bought or sold CELC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	new	-	669,298	669,298	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-36.04	-2,166	39,679	-%
May 15, 2024	NEA Management Company, LLC	unchanged	-	8,787,500	27,000,000	1.68%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	new	-	1,928,340	1,928,340	-%
May 15, 2024	MARSHALL WACE, LLP	new	-	2,350,400	2,350,400	-%
May 15, 2024	J. Goldman & Co LP	reduced	-71.08	-925,946	694,894	0.02%
May 15, 2024	SAMLYN CAPITAL, LLC	new	-	14,898,900	14,898,900	0.25%
May 15, 2024	Cresset Asset Management, LLC	unchanged	-	130,125	399,816	-%
May 15, 2024	Soleus Capital Management, L.P.	reduced	-20.56	5,641,860	37,396,900	2.78%
May 15, 2024	CAPTRUST FINANCIAL ADVISORS	reduced	-14.24	2,154,250	10,092,500	0.04%

Are Funds Buying or Selling CELC?

Are funds buying CELC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CELC

No. of Funds

Unveiling Celcuity Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	commodore capital lp	9.9%	2,492,886	SC 13G/A
Feb 14, 2024	venrock healthcare capital partners iii, l.p.	9.99%	2,476,980	SC 13G/A
Feb 14, 2024	ra capital management, l.p.	5.0%	1,286,960	SC 13G/A
Feb 14, 2024	perceptive advisors llc	6.1%	1,481,300	SC 13G/A
Feb 12, 2024	morgan stanley	9.1%	2,195,026	SC 13G/A
Feb 09, 2024	soleus capital master fund, l.p.	9.9%	2,623,890	SC 13G/A
Feb 07, 2024	laing lance g.	5.5%	1,421,036	SC 13G/A
Feb 07, 2024	sullivan brian f.	14.0%	3,648,665	SC 13G/A
Dec 26, 2023	perceptive advisors llc	5.7%	1,441,300	SC 13G
Feb 14, 2023	commodore capital lp	9.9%	2,257,412	SC 13G/A

Recent SEC filings of Celcuity Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 15, 2024	8-K	Current Report
May 13, 2024	8-K	Current Report
Apr 30, 2024	4	Insider Trading
Apr 26, 2024	4	Insider Trading
Apr 25, 2024	D/A	D/A
Apr 24, 2024	144	Notice of Insider Sale Intent
Apr 10, 2024	4	Insider Trading
Mar 29, 2024	8-K	Current Report
Mar 29, 2024	ARS	ARS

Peers (Alternatives to Celcuity Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Celcuity Inc News

Latest updates

Celcuity Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-1.6%	188	191	142	154	165	176	65.00	72.00	80.00	86.00	92.00	43.00	36.00	13.00	15.00	17.00	18.00	20.00	22.00	23.00	25.00
Current Assets	-1.6%	188	191	142	153	164	175	65.00	72.00	79.00	85.00	91.00	42.00	36.00	12.00	14.00	16.00	17.00	19.00	21.00	22.00	24.00
Cash Equivalents	1.8%	31.00	31.00	26.00	32.00	34.00	25.00	57.00	67.00	78.00	84.00	90.00	42.00	35.00	12.00	14.00	15.00	17.00	19.00	16.00	15.00	15.00
Net PPE	33.8%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	5.8%	54.00	51.00	49.00	43.00	42.00	42.00	22.00	19.00	18.00	17.00	17.00	16.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Current Liabilities	17.7%	17.00	14.00	13.00	7.00	6.00	7.00	7.00	4.00	4.00	3.00	3.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Shareholder's Equity	-4.3%	134	140	93.00	110	123	134	44.00	53.00	62.00	69.00	74.00	27.00	35.00	12.00	14.00	16.00	18.00	19.00	21.00	22.00	24.00
Retained Earnings	-13.5%	-181	-160	-141	-122	-108	-96.30	-84.72	-73.82	-63.86	-55.93	-49.17	-43.15	-29.11	-26.32	-23.77	-21.30	-19.09	-16.85	-15.04	-13.05	-11.33
Additional Paid-In Capital	5.2%	315	300	234	233	231	230	128	127	125	125	124	70.00	64.00	38.00	38.00	37.00	37.00	36.00	36.00	35.00	35.00
Shares Outstanding	19.4%	30.00	26.00	22.00	22.00	22.00	22.00	15.00	15.00	15.00	15.00	13.00	12.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	191	-	-	-	96.00	-	-	-	198	-	-	-	41.00	-	-	-	146	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	7.9%	-17,068	-18,535	-12,746	-9,662	-12,867	-9,479	-9,306	-11,289	-5,933	-6,124	-4,048	-7,617	-2,521	-2,107	-1,648	-1,556	-1,833	-1,703	-1,478	-1,226	-1,590
Share Based Compensation	7.1%	1,331	1,243	1,109	1,277	1,273	1,139	1,223	1,519	756	921	700	540	449	427	449	423	465	361	303	192	185
Cashflow From Investing	108.6%	3,536	-41,218	6,252	8,090	21,868	-143,985	-12.10	-22.99	-11.63	-9.94	-14.06	-26.97	-30.42	-13.88	-8.90	-20.98	-45.60	4,137	2,831	1,364	197
Cashflow From Financing	-78.2%	14,084	64,657	15.00	172	68.00	120,552	-108	-72.52	-46.29	54.00	52,791	14,346	25,851	63.00	-76.47	153	-1.44	32.00	-1.43	57.00	172

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CELC Income Statement

2024-03-31

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 20,647,559	$ 11,278,493
General and administrative	1,846,276	1,269,044
Total operating expenses	22,493,835	12,547,537
Loss from operations	(22,493,835)	(12,547,537)
Other income (expense)
Interest expense	(1,400,712)	(1,242,012)
Interest income	2,282,092	1,851,132
Other income, net	881,380	609,120
Net loss before income taxes	(21,612,455)	(11,938,417)
Income tax benefits
Net loss	$ (21,612,455)	$ (11,938,417)
Net loss per share, basic	$ (0.64)	$ (0.55)
Net loss per share, diluted	$ (0.64)	$ (0.55)
Weighted average common shares outstanding, basic	33,612,054	21,680,877
Weighted average common shares outstanding, diluted	33,612,054	21,680,877

CELC Balance Sheet

2024-03-31

Condensed Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 31,214,741	$ 30,662,774
Investments	146,447,843	149,919,974
Other current assets	9,860,535	10,007,849
Total current assets	187,523,119	190,590,597
Property and equipment, net	306,024	228,782
Operating lease right-of-use assets	351,911	400,019
Total Assets	188,181,054	191,219,398
Current Liabilities:
Accounts payable	5,276,690	5,076,699
Operating lease liabilities	181,882	184,950
Accrued expenses	11,237,509	8,927,094
Total current liabilities	16,696,081	14,188,743
Operating lease liabilities	182,079	225,922
Note payable, non-current	37,566,230	37,035,411
Total Liabilities	54,444,390	51,450,076
Commitments and Contingencies (Note 5)
Stockholders’ Equity:
Preferred stock, $0.001 par value: 2,500,000 shares authorized; 505,277 and 854,134 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	505	854
Common stock, $0.001 par value: 65,000,000 shares authorized; 30,773,895 and 25,506,012 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	30,774	25,506
Additional paid-in capital	315,393,843	299,818,965
Accumulated deficit	(181,688,458)	(160,076,003)
Total Stockholders’ Equity	133,736,664	139,769,322
Total Liabilities and Stockholders’ Equity	$ 188,181,054	$ 191,219,398

About Celcuity Inc

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

CEO	Mr. Brian F. Sullivan
WEBSITE	celcuity.com
INDUSTRY	Biotechnology
EMPLOYEES	45

Celcuity Inc Frequently Asked Questions

What is the ticker symbol for Celcuity Inc? What does CELC stand for in stocks?

CELC is the stock ticker symbol of Celcuity Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Celcuity Inc (CELC)?

As of Fri May 17 2024, market cap of Celcuity Inc is 523.1 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CELC stock?

You can check CELC's fair value in chart for subscribers.

What is the fair value of CELC stock?

You can check CELC's fair value in chart for subscribers. The fair value of Celcuity Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Celcuity Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CELC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Celcuity Inc a good stock to buy?

The fair value guage provides a quick view whether CELC is over valued or under valued. Whether Celcuity Inc is cheap or expensive depends on the assumptions which impact Celcuity Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CELC.